华泰柏瑞生物医药混合A(004905)利润分配表
| |
2025-12-31 |
2025-06-30 |
2024-12-31 |
2024-06-30 |
| 收入 |
192,819,875.95 |
206,145,776.08 |
-31,427,411.14 |
-38,397,765.41 |
| 利息合计 |
190,700.41 |
92,140.08 |
253,933.19 |
146,480.47 |
| 其中:存款利息收入 |
190,700.41 |
92,140.08 |
214,195.60 |
106,742.88 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
39,737.59 |
39,737.59 |
| 投资收益合计 |
166,496,039.09 |
76,619,132.03 |
-71,752,076.56 |
-61,349,745.20 |
| 其中:股票投资收益 |
162,954,705.50 |
73,736,699.95 |
-77,720,529.51 |
-65,222,093.61 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
240,476.80 |
71,696.88 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
3,541,333.59 |
2,882,432.08 |
5,727,976.15 |
3,800,651.53 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
25,269,944.37 |
129,132,496.58 |
39,807,807.20 |
22,766,370.57 |
| 其他收入 |
863,192.08 |
302,007.39 |
262,925.03 |
39,128.75 |
| 费用 |
12,314,992.18 |
5,204,463.92 |
6,783,855.37 |
3,158,208.42 |
| 管理人报酬 |
8,464,298.34 |
3,684,825.27 |
5,380,452.69 |
2,517,800.80 |
| 基金托管费 |
1,410,716.44 |
614,137.55 |
896,742.13 |
419,633.48 |
| 销售服务费 |
2,216,238.98 |
794,793.15 |
288,115.93 |
100,100.37 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
223,738.42 |
110,707.95 |
218,541.60 |
120,673.57 |
| 利润总额 |
180,504,883.77 |
200,941,312.16 |
-38,211,266.51 |
-41,555,973.83 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年